Skip to content

Rising adoption of Galleri testing and expanded strategic alliances result in Grail revising its cash burn estimate for 2025 to $310 million.

Increased Utilization of Galleri Test in Q2 2025, along with Established New Partnerships and Enhanced Cash Burn Forecasts, Highlighted in GRAIL, Inc.'s Earnings Discussion.

Rising utilization of Galleri test and increased partnerships lead to an adjusted cash burn...
Rising utilization of Galleri test and increased partnerships lead to an adjusted cash burn estimate of $310M for Grail in 2025

Rising adoption of Galleri testing and expanded strategic alliances result in Grail revising its cash burn estimate for 2025 to $310 million.

GRAIL, Inc., a pioneering company in early cancer detection, is making significant strides with its flagship product, the Galleri test. The company has reported notable milestones in financial performance, partnerships, and regulatory progress.

Financial Performance

GRAIL reported total revenue of $35.5 million for Q2 2025, marking an 11% year-over-year increase. U.S. Galleri revenue grew 21% to $34.2 million. Despite this revenue growth, GRAIL incurred a net loss of $114 million, including a $28 million impairment from Illumina acquisition-related intangibles. However, the company ended the quarter with $606.1 million in cash and updated its full-year 2025 cash burn guidance to no more than $310 million.

Partnerships and Collaborations

GRAIL has expanded its reach by partnering with Everlywell to increase access to the Galleri test. This partnership marks a significant step in broadening the test's market reach. Additionally, the company partnered with Rush University System for Health, making it the first health system in the Chicago area to offer the Galleri test.

Regulatory Milestones and Challenges

The Galleri test has not been cleared or approved by the FDA but is performed under CLIA regulations. However, the test faces regulatory uncertainty due to challenges over the FDA's authority to regulate Laboratory Developed Tests (LDTs). This could lead to increased competition if competitors introduce similar tests with less stringent requirements. GRAIL is working towards obtaining a Premarket Approval (PMA) for the Galleri test, which could strengthen its market position.

Future Outlook

GRAIL plans to present PATHFINDER 2 study results at ESMO in October, potentially aiding international expansion efforts. Despite regulatory challenges, GRAIL's management remains confident in its ability to navigate these issues, citing strong commercial momentum and growing test adoption.

The Galleri test is advancing with increasing revenue and partnerships, but regulatory uncertainty remains a significant challenge. GRAIL's pursuit of a PMA and its focus on international expansion are crucial for its future success.

Key milestones for GRAIL include the completion of a modular PMA submission to the FDA in the first half of 2026 and full clinical utility results from the 140,000 participant NHS Galleri study, expected to read out midyear. Management remains focused on executing regulatory and clinical milestones.

The growing repeat test rates for Galleri underscore positive momentum heading into the second half of 2025. With over 45,000 Galleri commercial tests sold in Q2 2025 and over 370,000 prescribed since launch, the test's adoption continues to grow.

Analysts have expressed concerns about cash burn trajectory, scalability of customer support, and robustness of international expansion plans. Management acknowledged operational challenges with the new Galleri automation platform. However, no major impact from tariffs is expected, as most laboratory and supplier operations are U.S.-based.

President Joshua J. Ofman stated that the positive predictive value (PPV) and specificity remained high in the clinical validation trials of Galleri. Management reaffirmed staying on track for U.S. Galleri revenue growth guidance of 20% to 30% for 2025. Ragusa outlined plans to present PATHFINDER 2 study results at ESMO in October.

[1] GRAIL, Inc. (GRAL) Q2 2025 Earnings Release (2025, July 27). Retrieved from https://ir.grail.com/news-releases/news-release-details/grail-inc-reports-second-quarter-2025-financial-results

[2] Chakraborty, A. (2025, July 27). GRAIL Inc (GRAL) Q2 2025 Earnings Call Transcript. Retrieved from https://seekingalpha.com/transcript/4434586-grail-inc-gral-q2-2025-earnings-call-transcript

[3] GRAIL, Inc. (GRAL) Q2 2025 Earnings Presentation (2025, July 27). Retrieved from https://ir.grail.com/static-files/98c0f418-e95b-4c55-86a6-3941c14391ef

[4] U.S. Food and Drug Administration. (2021). Laboratory Developed Tests (LDTs) and In Vitro Diagnostic Devices. Retrieved from https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests-ldts-and-in-vitro-diagnostic-devices

  1. GRAIL, a company focusing on health-and-wellness through early cancer detection, reported an 11% year-over-year increase in Q2 2025 revenue, totaling $35.5 million, while also announcing a net loss of $114 million.
  2. The financial performance of GRAIL saw growth in U.S. Galleri revenue, which jumped 21% to $34.2 million, despite the impairment from Illumina acquisition-related intangibles.
  3. Despite the success in financial performance, GRAIL's future outlook centers around navigating regulatory challenges, as the Galleri test has not been FDA-cleared or approved but performed under CLIA regulations.
  4. To gain a stronger market position, GRAIL is pursuing a Premarket Approval (PMA) for the Galleri test and plans to present PATHFINDER 2 study results at the ESMO conference in October, aiding international expansion efforts.
  5. The advancement of the Galleri test is evident with positive momentum, as repeat test rates increase and over 370,000 tests have been prescribed since its launch.
  6. In order to address concerns regarding cash burn trajectory, scalability of customer support, and robustness of international expansion plans, management emphasizes the importance of executing regulatory and clinical milestones in the coming months.

Read also:

    Latest